Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 19/20 | 1.00 |
| ▸ | STK3 | Q13188 | 5/20 | 1.00 |
| ▸ | STK26 | Q9P289 | 3/20 | 1.00 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.77 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.77 |
| ▸ | JAK2 | O60674 | 1/20 | 0.74 |
| ▸ | JAK1 | P23458 | 1/20 | 0.74 |
| ▸ | JAK3 | P52333 | 1/20 | 0.74 |
| ▸ | MST1 | P26927 | 1/20 | 0.74 |
| ▸ | STK4 | Q13043 | 1/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18967695 | 1.00 | LRRK2 (1.00) | LRRK2STK3STK26CHEK1CHEK2 | |
| SCHEMBL15401754 | 1.00 | LRRK2 (1.00) | LRRK2STK3STK26CHEK1CHEK2 | |
| SCHEMBL15400750 | 0.89 | LRRK2 (1.00) | LRRK2STK3STK26CHEK1CHEK2 | |
| SCHEMBL15400854 | 0.88 | LRRK2 (1.00) | LRRK2STK3STK26CHEK1CHEK2 | |
| SCHEMBL16854183 | 0.87 | LRRK2 (0.77) | LRRK2STK3STK26CHEK1CHEK2 | |
| SCHEMBL16854198 | 0.87 | LRRK2 (0.77) | LRRK2STK3STK26CHEK1CHEK2 | |
| SCHEMBL19884660 | 0.87 | LRRK2 (0.77) | LRRK2STK3STK26CHEK1CHEK2 | |
| SCHEMBL14162939 | 0.87 | CHEK1 (1.00) | LRRK2STK3STK26CHEK1CHEK2 | |
| SCHEMBL15400697 | 0.87 | LRRK2 (1.00) | LRRK2STK3STK26CHEK1CHEK2 | |
| SCHEMBL15401684 | 0.87 | LRRK2 (1.00) | LRRK2STK3STK26CHEK1CHEK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2867236-B1 | NOVEL 4-(SUBSTITUTED-AMINO)-7H-PYRROLO[2,3-D]PYRIMIDINES AS LRRK2 INHIBITORS | PFIZER (US) | 2017-06-14 | — | — | EP | claimed |
| US-9642855-B2 | Substituted pyrrolo[2,3-d]pyrimidines as LRRK2 inhibitors | PFIZER INC. (US) | 2017-05-09 | — | — | US | claimed |
| US-20150366874-A1 | Novel 4-(Substituted Amino)-7H-Pyrrolo[2,3-d]Pyrimidines As LRRK2 Inhibitors | PFIZER INC. (US) | 2015-12-24 | — | — | US | claimed |
| US-9156845-B2 | 4-(substituted amino)-7H-pyrrolo[2,3-d] pyrimidines as LRRK2 inhibitors | PFIZER INC. (US) | 2015-10-13 | — | — | US | claimed |
| US-20140005183-A1 | Novel 4-(Substituted Amino)-7H-Pyrrolo[2,3-d] Pyrimidines As LRRK2 Inhibitors | PFIZER (US) | 2014-01-02 | — | — | US | claimed |
| US-11661461-B2 | Phospho-Rab antibodies, assays and methods of use thereof | DENALI THERAPEUTICS INC. (US) | 2023-05-30 | — | — | US | disclosed |
| US-20210147573-A1 | PHOSPHO-RAB ANTIBODIES, ASSAYS AND METHODS OF USE THEREOF | DENALI THERAPEUTICS INC. (US) | 2021-05-20 | — | — | US | disclosed |
| WO-2018232278-A2 | PHOSPHO-RAB ANTIBODIES, ASSAYS AND METHODS OF USE THEREOF | DENALI THERAPEUTICS INC. (US) | 2018-12-20 | — | — | WO | disclosed |
| EP-2867236-B1 | NOVEL 4-(SUBSTITUTED-AMINO)-7H-PYRROLO[2,3-D]PYRIMIDINES AS LRRK2 INHIBITORS | PFIZER (US) | 2017-06-14 | — | — | EP | disclosed |
| EP-2867236-B1 | NOVEL 4-(SUBSTITUTED-AMINO)-7H-PYRROLO[2,3-D]PYRIMIDINES AS LRRK2 INHIBITORS | PFIZER (US) | 2017-06-14 | — | — | EP | disclosed |
| US-9642855-B2 | Substituted pyrrolo[2,3-d]pyrimidines as LRRK2 inhibitors | PFIZER INC. (US) | 2017-05-09 | — | — | US | disclosed |
| US-9642855-B2 | Substituted pyrrolo[2,3-d]pyrimidines as LRRK2 inhibitors | PFIZER INC. (US) | 2017-05-09 | — | — | US | disclosed |
| US-9642855-B2 | Substituted pyrrolo[2,3-d]pyrimidines as LRRK2 inhibitors | PFIZER INC. (US) | 2017-05-09 | — | — | US | disclosed |
| US-20150366874-A1 | Novel 4-(Substituted Amino)-7H-Pyrrolo[2,3-d]Pyrimidines As LRRK2 Inhibitors | PFIZER INC. (US) | 2015-12-24 | — | — | US | disclosed |
| US-20150366874-A1 | Novel 4-(Substituted Amino)-7H-Pyrrolo[2,3-d]Pyrimidines As LRRK2 Inhibitors | PFIZER INC. (US) | 2015-12-24 | — | — | US | disclosed |
| US-20150366874-A1 | Novel 4-(Substituted Amino)-7H-Pyrrolo[2,3-d]Pyrimidines As LRRK2 Inhibitors | PFIZER INC. (US) | 2015-12-24 | — | — | US | disclosed |
| US-9156845-B2 | 4-(substituted amino)-7H-pyrrolo[2,3-d] pyrimidines as LRRK2 inhibitors | PFIZER INC. (US) | 2015-10-13 | — | — | US | disclosed |
| US-9156845-B2 | 4-(substituted amino)-7H-pyrrolo[2,3-d] pyrimidines as LRRK2 inhibitors | PFIZER INC. (US) | 2015-10-13 | — | — | US | disclosed |
| US-9156845-B2 | 4-(substituted amino)-7H-pyrrolo[2,3-d] pyrimidines as LRRK2 inhibitors | PFIZER INC. (US) | 2015-10-13 | — | — | US | disclosed |
| US-20140005183-A1 | Novel 4-(Substituted Amino)-7H-Pyrrolo[2,3-d] Pyrimidines As LRRK2 Inhibitors | PFIZER (US) | 2014-01-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210147573-A1 | PHOSPHO-RAB ANTIBODIES, ASSAYS AND METHODS OF USE THEREOF | RAB10, GTPBP10, RABL3 | LRRK2 16/4885STK3 604/4885STK26 688/4885 |
| US-20150366874-A1 | Novel 4-(Substituted Amino)-7H-Pyrrolo[2,3-d]Pyrimidines As LRRK2 Inhibitors | LRRK2, PARK7, BRCA1 | LRRK2 1/4885STK3 241/4885STK26 251/4885 |
| US-11661461-B2 | Phospho-Rab antibodies, assays and methods of use thereof | RAB10, GTPBP10, RAB8A | LRRK2 19/4885STK3 1067/4885STK26 1082/4885 |
| US-20140005183-A1 | Novel 4-(Substituted Amino)-7H-Pyrrolo[2,3-d] Pyrimidines As LRRK2 Inhibitors | LRRK2, PARK7, BRCA1 | LRRK2 1/4885STK3 241/4885STK26 251/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.